Item 1A. Risk Factors
2K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the period ended December 31, 2022. For further discussion of our risk factors, refer to Item 1A. "Risk Factors" contained in our Annual Report on Form 10-K for the period ended December 31, 2022.
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
The following table provides information with respect to purchases of our ordinary shares during the third quarter of 2023:
| Period | Total number of shares purchased (000's) (a) (b) | Average price paid per share (a) (b) | Total number of shares purchased as part of program (000's) (a) | Approximate dollar value of shares still available to be purchased under the program ($000's) (a) | ||||||||||||||||||||||
| July 1 - July 31 | 0.6 | $ | 191.26 | — | $ | 2,899,773 | ||||||||||||||||||||
| August 1 - August 31 | 385.5 | 202.48 | 384.6 | 2,821,903 | ||||||||||||||||||||||
| September 1 - September 30 | 402.7 | 203.55 | 402.7 | 2,739,934 | ||||||||||||||||||||||
| Total | 788.8 | $ | 203.02 | 787.3 |
(a) Share repurchases are made from time to time in accordance with management's capital allocation strategy, subject to market conditions and regulatory requirements. In February 2022, our Board of Directors authorized a share repurchase program of up to $3.0 billion of our ordinary shares (2022 Authorization). During the three months ended September 30, 2023, we repurchased approximately $160 million of our ordinary shares under the 2022 Authorization, leaving $2.7 billion remaining.
(b) We may also reacquire shares outside of the repurchase program from time to time in connection with the surrender of shares to cover taxes on vesting of share-based awards. We reacquired 540 shares in July and 921 shares in August in transactions outside of the repurchase programs.
Table of Contents
Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information